JYLAMVO Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Jylamvo, and when can generic versions of Jylamvo launch?

Jylamvo is a drug marketed by Shorla and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-three patent family members in eighteen countries.

The generic ingredient in JYLAMVO is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jylamvo

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for JYLAMVO?
What are the global sales for JYLAMVO?
What is Average Wholesale Price for JYLAMVO?

Summary for JYLAMVO

International Patents:	23
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	137
Patent Applications:	4,333
Drug Prices:	Drug price information for JYLAMVO
What excipients (inactive ingredients) are in JYLAMVO?	JYLAMVO excipients list
DailyMed Link:	JYLAMVO at DailyMed

Drug patent expirations by year for JYLAMVO

Pharmacology for JYLAMVO

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

US Patents and Regulatory Information for JYLAMVO

JYLAMVO is protected by six US patents.

Patents protecting JYLAMVO

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shorla	JYLAMVO	methotrexate	SOLUTION;ORAL	212479-001	Nov 29, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Shorla	JYLAMVO	methotrexate	SOLUTION;ORAL	212479-001	Nov 29, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for JYLAMVO

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Nordic Group B.V.	Nordimet	methotrexate	EMEA/H/C/003983 Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.	Authorised	no	no	no	2016-08-18
Therakind (Europe) Limited	Jylamvo	methotrexate	EMEA/H/C/003756 In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over.	Authorised	no	no	no	2017-03-29
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for JYLAMVO

See the table below for patents covering JYLAMVO around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Spain	2908447		⤷ Sign Up
Cyprus	1125033		⤷ Sign Up
European Patent Office	3212237	FORMULATION DE MÉTHOTREXATE (METHOTREXATE FORMULATION)	⤷ Sign Up
Canada	3002493	FORMULATION DE METHOTREXATE (METHOTREXATE FORMULATION)	⤷ Sign Up
Japan	2021138748	メトトレキサート製剤 (METHOTREXATE FORMULATION)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration